Ionis Pharmaceuticals’ Heart Drug Failure: A Ripple Through the Biotech Landscape
(SeaPRwire) – By: Robert Kensington
In the high-stakes world of biotech, Ionis Pharmaceuticals’ recent setback with its heart drug eplontersen in the Phase 3 CARDIO-TTRansform trial has sent shockwaves through the industry. The failure to meet the primary endpoint has not only hit the company’s stock price but has also reshaped the competitive landscape for treatments related to transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Ionis Pharmaceuticals saw its stock drop around 17 – 20% on Thursday, a significant decline that extends its year-to-date losses. This was a direct result of the news that the Phase 3 trial for eplontersen had failed to show a reduction in the risk of heart-related deaths and repeat cardiovascular events in patients with ATTR-CM over the 140-week study period when compared to a placebo. AstraZeneca, its partner in the trial, also took a hit, with its U.S.-listed stock falling around 9%. This shows just how much both companies had riding on the success of this trial.
The trial had enrolled a patient population where 57% were already on a stabilizer drug at the start, and another 24% started one during the study. In this context, eplontersen showed no treatment effect, which is a major concern given the prevalence of stabilizer use in clinical practice. However, there was a silver lining. In patients who were not on a stabilizer drug, eplontersen showed a 29% reduction in the combined risk of cardiovascular death and repeat events. The drug also managed to produce strong, sustained reductions in transthyretin protein levels and hit several secondary endpoints.
But analysts were not convinced that this partial win was enough to move forward. Stifel’s Paul Matteis noted that trying to approach regulators with these data would be a stretch. Neither Ionis nor AstraZeneca announced plans to seek regulatory approval or run a follow-up study. CEO Brett Monia acknowledged the disappointment, pointing out the changing treatment landscape where more patients now start on stabilizers before entering trials. The full dataset will be presented at the European Society of Cardiology Congress in August 2026.
For Ionis specifically, this failure cuts off expected profit-sharing, royalties, and future milestone payments tied to eplontersen’s success in heart disease. The company had likely banked on the drug’s success to drive growth and expand its market presence in the cardiovascular drug space. Now, it has to reevaluate its strategies and financial projections.
The impact on the competition has been significant as well. Alnylam Pharmaceuticals and BridgeBio both jumped double digits on Thursday. With eplontersen’s future in ATTR-CM now uncertain, Alnylam’s Amvuttra looks set to hold its position as the only RNA-silencing therapy in the space. Stifel’s Matteis called it a “huge positive” for Amvuttra. Pfizer’s Vyndamax, already the market leader with over $6 billion in sales last year, also stands to benefit from one fewer competitor. This shake-up in the market presents new opportunities for these rival companies to gain market share and expand their product portfolios.
Jefferies analyst Michael Leuchten pointed out that the bigger issue for AstraZeneca isn’t just the revenue miss but the credibility hit. The company had entered the readout with high confidence, given its reputation for good trial design ability. Wall Street’s consensus on IONS heading into Thursday was Strong Buy, with an average price target of $104.61. Those ratings are now likely to be revised in the wake of this disappointing news.
The trading volume in IONS hit around 3 million shares on Thursday, well above the three-month daily average of 1.86 million. This increased volume indicates the high level of market interest and concern surrounding this development. Investors are closely watching how Ionis will respond to this setback and what it means for the future of the company’s drug pipeline and overall business strategy.
This event serves as a reminder of the unpredictable nature of drug development. Even with extensive research and trials, there are no guarantees of success. Ionis will now need to regroup, assess the data from the trial more thoroughly, and decide on the best course of action. Whether it’s modifying the drug, targeting a different patient subset, or exploring new partnerships, the company’s next moves will be crucial in determining its future in the biotech market. The competition, on the other hand, will be looking to capitalize on Ionis’ misstep and solidify their own positions in the ATTR-CM treatment space.
Author bio: Robert Kensington, an overseas entrepreneurial veteran with decades of experience in real-economy industrial investment and expansion.